Jun Siong Low

Jun Siong Low

Auto-generated profile, based on publicly available information

Jun Siong Low

Institute for Research in Biomedicine, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Cell
Verified
Journal Article
Closed access
RNRoni Nowarski
Roni Nowarski
RJRuaidhrí Jackson
Ruaidhrí Jackson
NGNicola Gagliani
Nicola Gagliani
MZMarcel R. de Zoete
Marcel R. de Zoete
NPNoah W. Palm
Noah W. Palm
RFRichard A. Flavell
Richard A. Flavell

3 September 2021 in Science
Verified
Journal Article
Open access
DPDora Pinto
Dora Pinto
MSMaximilian M. Sauer
Maximilian M. Sauer
NCNadine Czudnochowski
Nadine Czudnochowski
JLJun Siong Low
Jun Siong Low
MTM. Alejandra Tortorici
M. Alejandra Tortorici
DVDavid Veesler
David Veesler
Targeting a range of betacoranaviruses: In the past 20 years, three highly pathogenic β-coronaviruses have crossed from animals to humans, including the most recent: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A spike protein that decorates these viruses has an S1 domain that binds host cell receptors and an S2 domain that fuses the viral and cell membranes to allow cell entry. The S1 domain is the target of many neutralizing antibodies but is more genetically variable than S2, and antibodies can exert selective pressure, leading to resistant variants. Pinto et al . identified five monoclonal antibodies that interact with a helix in the S2 domain. The most broadly neutralizing antibody inhibited all β-coronavirus subgenera and reduced viral burden in hamsters infected with SARS-CoV-2. —VV

12 August 2022 in Science
Verified
Journal Article
Open access
JLJun Siong Low
Jun Siong Low
JJJosipa Jerak
Josipa Jerak
MTM. Alejandra Tortorici
M. Alejandra Tortorici
MMMatthew McCallum
Matthew McCallum
DPDora Pinto
Dora Pinto
FSFederica Sallusto
Federica Sallusto
The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion. Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that bind to all human-infecting coronavirus spike proteins from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune donors. These mAbs recognize the fusion peptide and acquire affinity and breadth through somatic mutations. Despite targeting a conserved motif, only some mAbs show broad neutralizing activity in vitro against alpha- and betacoronaviruses, including animal coronaviruses WIV-1 and PDF-2180. Two selected mAbs also neutralize Omicron BA.1 and BA.2 authentic viruses and reduce viral burden and pathology in vivo. Structural and functional analyses showed that the fusion peptide–specific mAbs bound with different modalities to a cryptic epitope hidden in prefusion stabilized spike, which became exposed upon binding of angiotensin-converting enzyme 2 (ACE2) or ACE2-mimicking mAbs.

1 January 2020 in Cell
Verified
Journal Article
Closed access
AJAbigail Jarret
Abigail Jarret
RJRuaidhrí Jackson
Ruaidhrí Jackson
CDCoco Duizer
Coco Duizer
MHMarc E. Healy
Marc E. Healy
JZJun Zhao
Jun Zhao
RFRichard A. Flavell
Richard A. Flavell

1 August 2019 in Cell
Verified
Journal Article
Closed access
MVMaria Carolina Amezcua Vesely
Maria Carolina Amezcua Vesely
PPParis Pallis
Paris Pallis
PBPiotr Bielecki
Piotr Bielecki
JLJun Siong Low
Jun Siong Low
JZJun Zhao
Jun Zhao
RFRichard A. Flavell
Richard A. Flavell

18 June 2021 in Science
Verified
Journal Article
Open access
PDF file
JLJun Siong Low
Jun Siong Low
DVDaniela Vaqueirinho
Daniela Vaqueirinho
FMFederico Mele
Federico Mele
MFMathilde Foglierini
Mathilde Foglierini
JJJosipa Jerak
Josipa Jerak
ACAntonino Cassotta
Antonino Cassotta
Probing CD4 T cell immunity to SARS-CoV-2: A better understanding of CD4 + T cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial to the design of effective next-generation vaccines. Low et al. defined and estimated the CD4 + T cell repertoire of convalescent COVID-19 patients. After sorting various CD4 + T cell subsets, they generated numerous T cell clones that reacted to the SARS-CoV-2 spike protein. A large number of T cell clones from almost all individuals recognized a small conserved immunodominant region within the spike protein receptor-binding domain (RBD). The researchers isolated T cell clones that broadly reacted to the spike protein of other coronaviruses, providing evidence for the recall of preexisting cross-reactive memory T cells after SARS-CoV-2 infection. Science , abg8985, this issue p. 1336